Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Autore:
Le, WD; Jankovic, J;
Indirizzi:
Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 , Dept Neurol, Houston, TX 77030 USA
Titolo Testata:
DRUGS & AGING
fascicolo: 6, volume: 18, anno: 2001,
pagine: 389 - 396
SICI:
1170-229X(2001)18:6<389:ADRANI>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
LEVODOPA-INDUCED TOXICITY; RADICALS IN-VITRO; SUBSTANTIA-NIGRA; MESENCEPHALIC CULTURES; BROMOCRIPTINE PROTECTS; OXIDATIVE STRESS; CELL-DEATH; ANTIPARKINSONIAN DRUGS; CEREBRAL-ISCHEMIA; BODY FORMATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Le, WD Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Neurol, Houston, TX 77030 USA
Citazione:
W.D. Le e J. Jankovic, "Are dopamine receptor agonists neuroprotective in Parkinson's disease?", DRUG AGING, 18(6), 2001, pp. 389-396

Abstract

Dopamine receptor agonists are playing an increasingly important role in the treatment of not only patients with advanced Parkinson's disease and those with levodopa-induced motor fluctuations, but also in the early treatment of the disease. This shift has been largely due to the demonstrated levodopa-sparing effect of dopamine agonists and their putative neuroprotective effect, with evidence for the latter being based largely on experimental invitro and in vivo studies. In this article we review the evidence for neuroprotection by the dopamine agonists pramipexole, ropinirole, pergolide, bromocriptine and apomorphine in cell cultures and animal models of injury tothe substantia nigra. Most of the studies suggest that dopamine agonists may have neuroprotective effects via direct scavenging of free radicals or increasing the activities of radical-scavenging enzymes, and enhancing neurotrophic activity. However, the finding that pramipexole can normalise mitochondrial membrane potential and inhibit activity of caspase-3 in cytoplasmic hybrid cells derivedfrom mitochondrial DNA of patients with nonfamilial. Alzheimer's disease suggests an even broader implication for the neuroprotective role of dopamine agonists. Although the clinical evidence for neuroprotection by dopamine agonists is still limited, the preliminary results from several ongoing clinical trials are promising. Several longitudinal studies are currently in progress designed to demonstrate a delay or slowing of progression of Parkinson's disease using various surrogate markers of neuronal degeneration suchas F-18-levodopa positron emission tomography and I-123 beta -CIT (carbomethoxy-beta -4-iodophenyl-nortropane) single positron emission computed tomography. The results of these experimental and clinical studies will improveour understanding of the action of dopamine agonists and provide critical information needed for planning future therapeutic strategies for Parkinson's disease and related neurodegenerative disorders.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:12:07